The Motley Fool

Why the Clinuvel Pharmaceuticals share price is down 8% today

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price has fallen more than 9% during trading today. CUV shares opened at $35.57 this morning but at the time of writing, the price has dropped to $32.99, a fall of around 8.49%.

The reasons for this drop are not entirely clear, although it may involve some profit taking. At today’s open price, Clinuvel shares were up 97.6% YTD, and 62% over the last three months. These price gains were likely assisted by the company’s inclusion in the S&P/ASX 200 (INDEXASX: XJO) index as of 24 June.

Today’s drop may also involve a delayed reaction to Clinuvel’s ‘communiqué’, which was released to the market yesterday before opening. Clinuvel provided an update on the pending US Food and Drug Administration review of its SCENESSE (afamelanotide) product, which has been extended by three months to 6 October 2019.

Clinuvel hopes that SCENESSE (if approved) will be useful in treating erythropoietic protoporphyria (EPP), of which (according to Clinuvel) there is little effective treatment currently available to US patients, many of whom travel to Europe for treatment.

In its release, the company stated: “although the extension… for three months is not our favoured outcome, we remind all stakeholders that if insurmountable outstanding scientific issues were identified during the filing stage, and/or major deficiencies were identified during their due diligence to date, the FDA has always been able to issue a Refusal to File (RTF) and/ or recommend a withdrawal of the NDA. Since these events had not occurred, we embrace a cautious optimism and bear the patience to a long-awaited outcome.”

For a stock getting ready to rocket in the other direction, don't miss this unique ASX-listed company set to profit off the coming marijuana boom.

One ASX Stock For An Estimated $US22 Billion Marijuana Market

A little-known ASX company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

And make no mistake – it is coming. To the tune of an estimated $US22 billion.

Cannabis legalisation is sweeping over North America, and full legalisation arrived in Canada in October 2018.

Here's the best part: we think there's one ASX stock that's uniquely positioned to profit immensely from this explosive new industry... taking savvy investors along for what could be one heck of a ride.

AND, this is the first time The Motley Fool Australia has EVER put a BUY recommendation on a marijuana stock.

Simply click below to learn more on how you can profit from the coming cannabis boom.

Click here to find out more


Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

5 ASX Stocks for Building Wealth After 50

I just read that Warren Buffett, the world’s best investor, made over 99% of his massive fortune after his 50th birthday.

It just goes to show you… it’s never too late to start securing your financial future.

And Motley Fool Chief Investment Advisor Scott Phillips just released a brand-new report that reveals five of our favourite ASX stocks for building wealth after 50.

– Each company boasts strong growth prospects over the next 3 to 5 years…

– Most importantly each pays a generous dividend, fully franked.

Simply click here to find out how you can claim your FREE copy of “5 ASX Stocks for Building Wealth After 50.”

See the stocks now